NZ714558A - Formulation comprising a hypolipidemic agent - Google Patents

Formulation comprising a hypolipidemic agent

Info

Publication number
NZ714558A
NZ714558A NZ714558A NZ71455814A NZ714558A NZ 714558 A NZ714558 A NZ 714558A NZ 714558 A NZ714558 A NZ 714558A NZ 71455814 A NZ71455814 A NZ 71455814A NZ 714558 A NZ714558 A NZ 714558A
Authority
NZ
New Zealand
Prior art keywords
formula
formulation
hypolipidemic agent
compounds
present
Prior art date
Application number
NZ714558A
Other languages
English (en)
Inventor
Jitendre D Patel
Prakash Davadra
Snehal Patel
Shafiq Sheikh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of NZ714558A publication Critical patent/NZ714558A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ714558A 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent NZ714558A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (enExample) 2013-07-25 2013-07-25
PCT/IN2014/000489 WO2015011730A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Publications (1)

Publication Number Publication Date
NZ714558A true NZ714558A (en) 2017-02-24

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ714558A NZ714558A (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent

Country Status (22)

Country Link
US (2) US9610277B2 (enExample)
EP (1) EP3024446A1 (enExample)
JP (1) JP2016523895A (enExample)
KR (1) KR101786843B1 (enExample)
CN (1) CN105407873A (enExample)
AP (1) AP2015008876A0 (enExample)
AR (1) AR097067A1 (enExample)
AU (1) AU2014294548B2 (enExample)
BR (1) BR112015031878A2 (enExample)
CA (1) CA2917923A1 (enExample)
EA (1) EA201690072A1 (enExample)
GE (1) GEP20186825B (enExample)
HK (1) HK1219222A1 (enExample)
IN (1) IN2013MU02470A (enExample)
MA (1) MA38865A1 (enExample)
MX (1) MX374628B (enExample)
NZ (1) NZ714558A (enExample)
PH (1) PH12015502802A1 (enExample)
SG (1) SG11201509798PA (enExample)
TW (1) TW201545773A (enExample)
WO (1) WO2015011730A1 (enExample)
ZA (1) ZA201508682B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136290A1 (en) 2006-05-23 2007-11-29 Intel Corporation Millimeter-wave communication system with directional antenna and one or more millimeter-wave reflectors
EP3009136A1 (en) 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
UA114360C2 (uk) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (enExample) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
EP3551180B1 (en) 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
SK695A3 (en) 1992-07-03 1995-07-11 Smithkline Beecham Plc Heterocyclic compounds method of their production and using
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
US6075140A (en) 1995-04-28 2000-06-13 Daiichi Pharmaceutical Co., Ltd. Pentacyclic compound
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1124807A1 (en) 1997-10-27 2001-08-22 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
WO2000023445A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
ES2449194T3 (es) 2000-01-19 2014-03-18 Cadila Healthcare Limited Compuestos que tienen actividades hipolipidémica e hipocolesterolémica, procedimiento para su preparación y composiciones farmacéuticas que los contienen
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
JP4261546B2 (ja) 2003-09-26 2009-04-30 三菱レイヨン株式会社 電気泳動装置および電気泳動法
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
KR101250632B1 (ko) * 2006-02-22 2013-04-03 에자이 알앤드디 매니지먼트 가부시키가이샤 안정화 의약 조성물
US20090196923A1 (en) 2006-04-26 2009-08-06 Jayanta Kumar Mandal Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
ES2441665T3 (es) 2009-11-26 2014-02-05 Genfit Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos
MX2013004123A (es) * 2010-10-12 2013-12-16 Univ Johns Hopkins Composiciones antitusigenas que comprenden memantina.
EP3009136A1 (en) * 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
UA114360C2 (uk) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (enExample) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
MA38865A1 (fr) 2017-12-29
US20160136131A1 (en) 2016-05-19
EA201690072A1 (ru) 2016-06-30
TW201545773A (zh) 2015-12-16
CA2917923A1 (en) 2015-01-29
PH12015502802A1 (en) 2016-03-14
KR101786843B1 (ko) 2017-10-18
SG11201509798PA (en) 2016-02-26
WO2015011730A1 (en) 2015-01-29
US20170266158A1 (en) 2017-09-21
EP3024446A1 (en) 2016-06-01
MX2015016971A (es) 2016-04-25
US10098868B2 (en) 2018-10-16
AU2014294548A1 (en) 2015-12-17
GEP20186825B (en) 2018-02-26
BR112015031878A2 (pt) 2017-07-25
CN105407873A (zh) 2016-03-16
IN2013MU02470A (enExample) 2015-06-26
KR20160013150A (ko) 2016-02-03
AP2015008876A0 (en) 2015-11-30
AU2014294548B2 (en) 2017-08-10
AR097067A1 (es) 2016-02-17
US9610277B2 (en) 2017-04-04
HK1219222A1 (zh) 2017-03-31
ZA201508682B (en) 2017-03-29
JP2016523895A (ja) 2016-08-12
MX374628B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
NZ716840A (en) Combination formulation of two antiviral compounds
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CA2875877C (en) Syk inhibitors
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX361618B (es) Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201270216A1 (ru) Фармацевтический состав
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
MX390763B (es) Compuestos de tetraciclina
PH12016500577A1 (en) Piperazine derivatives and the use thereof as medicament
WO2014166836A8 (en) Growth hormone compound formulation
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
IN2013MU02442A (enExample)
TN2015000524A1 (en) Pharmaceutical compositions
SA112330437B1 (ar) تركيبات دوائية محتوية على عامل منوم او مخدر وطريقة تحضيرها
TN2013000137A1 (en) Pharmaceutical compositions containing a dgat 1 inhibitor

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed